Inductive Bio, NYC-based technology company developing a machine learning (ML) platform designed to accelerate the compound optimization process, raised $4.3M in Seed funding.
The round was led by a16z Bio + Health and Lux Capital, with participation from Character, Bessemer Venture Partners, Alleycorp, and others.
The company intends to use the funds to expand operations and its development efforts.
Co-founded by Josh Haimson and Ben Birnbaum, Inductive Bio is a technology company developing a machine learning (ML) platform designed to accelerate the compound optimization process, a critical and time-consuming step in developing new therapeutics. By building datasets and ML models designed to map the drivers of small molecule Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET), Inductive’s platform allows scientists to optimize initial compounds into leads and development candidates faster and with a better balance of ADMET properties.
One of Inductive’s early partners is Denali Therapeutics, who is leveraging Inductive’s ML capabilities for ADME property predictions. Denali has integrated custom ADME models from Inductive into their small molecule drug design platform to support rapid, data-driven decision making.
Ankit Mahadevia, M.D., a serial biotech entrepreneur, former Venture partner at Atlas Ventures, and co-founder of nine therapeutics companies, also joined Inductive’s advisory board.
FinSMEs
13/12/2023